CPR's Tom McGarity has an op-ed this morning in the Austin American Statesman on Wyeth vs. Levine, the Supreme Court case testing an assertion by pharmaceutical manufacturer Wyeth that FDA approval of its proposed drug label shields the company from tort litigation over harm that drug subsequently causes. The Court heard oral arguments on the case on November 3, and a ruling is expected later this term.
The case arose out of one of those medical disaster stories we all fear. Diana Levine went to visit a doctor, complaining of a migraine. Her treatment included an injection of Wyeth's anti-nausea drug, phenergan. The label on the drug carries a caution about the so-called IV-push method of injection -- a shot. The better method is an IV-drip -- where a bottle is hung and the drug introduced more slowly into the vein. The danger is that the drug will get into an artery, a complication that is apparently taken off the table with an IV-drip, but possible, if uncommon with IV-push. Levine received phenergan via IV-push, things went wrong, the drug reached her artery, and tissue began to die. Before the saga was over, her arm was amputated, and her career as a professional guitarist effectively over.
She sued Wyeth, and in court, the company argued that because their label merely cautioning, not instructing, against IV-push was approved by the FDA, that they're not liable.
McGarity writes:
The question before the Supreme Court deals with an abstract legal rule called the pre-emption doctrine. The Constitution says that a state law that conflicts with federal law is null and void. Wyeth argues that because its label was approved by the U.S. Food and Drug Administration, Vermont's more protective common law is pre-empted....
If regulatory agencies were perfect, common law liability might be unnecessary. But by all accounts, FDA and other federal agencies are starved for resources and often more concerned with meeting industry demands for expeditious approvals than with protecting the public.
Of course, pharmaceutical litigation is hardly the only area in which pre-emption would shield manufacturers from liability for dangerously defective products. A broad victory for Wyeth will make it harder to hold manufacturers of other products to account, too, including manufacturers of defective toys, poorly designed automobiles and flammable clothing.
The full op-ed is in this morning's Austin American Statesman. McGarity's new book on preemption comes out December 2: The Preemption War: When Federal Bureaucracies Trump Local Juries. (Amazon and others have the book in stock already.) There's an interesting Q/A with Professor McGarity on the University of Texas website, here.
Showing 2,829 results
Matthew Freeman | November 28, 2008
CPR’s Tom McGarity has an op-ed this morning in the Austin American Statesman on Wyeth vs. Levine, the Supreme Court case testing an assertion by pharmaceutical manufacturer Wyeth that FDA approval of its proposed drug label shields the company from tort litigation over harm that drug subsequently causes. The Court heard oral arguments on the […]
Matthew Freeman | November 28, 2008
If you’re a Washington, D.C., commuter, it’s hard these days to miss the series of transit ads from Chevron on subway walls, bus shelter windows, and even the exteriors of subway cars. “I will finally get a programmable thermostat,” says one, over the picture of a concerned woman. “I will at least consider a hybrid,” […]
Matt Shudtz | November 25, 2008
Every time energy prices spike, oil companies (and their allies in Washington) start talking up oil shale. It happened just before World War I, it happened after the 1973 oil embargo, and it’s happening again now. Oil shale, the hucksters tell us, is the answer to America’s energy problems. Huge deposits of the stuff lie […]
James Goodwin | November 24, 2008
Much is being made of the outgoing Bush Administration’s “midnight regulations,” and with good reason, too. Many of them roll back crucial protections for public health, safety, and the environment. So far, they include relaxed requirements for building filthy coal plants near national parks and the elimination of a requirement mandating that federal agencies consult […]
Matthew Freeman | November 21, 2008
In January, “committed environmentalist” Henry Waxman will take the chair of the powerful House Energy and Commerce Committee, the body through which environmental legislation – and most significantly, climate change legislation – will pass on its way to the floor of the House of Representatives next year. As it happens, Representative Waxman is a charter […]
Margaret Clune Giblin | November 20, 2008
One important environmental challenge facing soon-to-be-President Obama is how to reinvigorate the National Forest System’s environmental protections. The system encompasses 192 million acres of land, which – to the constant amazement of those of us on the East Coast – represents about 8 percent of the total land area of the United States (roughly equivalent […]
Matt Shudtz | November 19, 2008
Last Friday, the American University Washington College of Law and the Robert L. Habush Endowment of the American Association for Justice hosted a conference on emerging ideas in consumer product safety. CPR Member Scholar Sid Shapiro opened the day with a presentation of a new paper he’s written with Professors Ruth Ruttenberg (National Labor College) […]
Shana Campbell Jones | November 18, 2008
Bigfoot lives, and he’s not hiding out from the paparazzi somewhere in the Pacific Northwest. He drives more than 630,000 vehicles. He is the largest consumer of energy in the United States, costing taxpayers about $14.5 billion. He generates about 100 million metric tons of carbon dioxide yearly, approximately 1.4 percent of all U.S. greenhouse […]
Sidney A. Shapiro | November 17, 2008
The Bush Administration’s penchant for secrecy was one of the most corrosive aspects of the way it ran the government these last eight years. This preference for conducting government business behind closed doors ran the gamut from military and foreign policy, where secrecy is more easily justified, to regulatory policy, where it is much less […]